32 lines
No EOL
1.3 KiB
JSON
32 lines
No EOL
1.3 KiB
JSON
{
|
|
"rejected_claims": [
|
|
{
|
|
"filename": "glp-1-cost-effectiveness-requires-long-term-risk-bearing-because-medical-savings-lag-drug-costs-by-12-18-months.md",
|
|
"issues": [
|
|
"missing_attribution_extractor"
|
|
]
|
|
},
|
|
{
|
|
"filename": "glp-1-receptor-agonists-show-50-percent-ovarian-cancer-reduction-and-14-percent-breast-cancer-reduction-in-female-users.md",
|
|
"issues": [
|
|
"missing_attribution_extractor"
|
|
]
|
|
}
|
|
],
|
|
"validation_stats": {
|
|
"total": 2,
|
|
"kept": 0,
|
|
"fixed": 2,
|
|
"rejected": 2,
|
|
"fixes_applied": [
|
|
"glp-1-cost-effectiveness-requires-long-term-risk-bearing-because-medical-savings-lag-drug-costs-by-12-18-months.md:set_created:2026-03-19",
|
|
"glp-1-receptor-agonists-show-50-percent-ovarian-cancer-reduction-and-14-percent-breast-cancer-reduction-in-female-users.md:set_created:2026-03-19"
|
|
],
|
|
"rejections": [
|
|
"glp-1-cost-effectiveness-requires-long-term-risk-bearing-because-medical-savings-lag-drug-costs-by-12-18-months.md:missing_attribution_extractor",
|
|
"glp-1-receptor-agonists-show-50-percent-ovarian-cancer-reduction-and-14-percent-breast-cancer-reduction-in-female-users.md:missing_attribution_extractor"
|
|
]
|
|
},
|
|
"model": "anthropic/claude-sonnet-4.5",
|
|
"date": "2026-03-19"
|
|
} |